美国Quidel Corporation 
美国Quidel公司(Quidel Corporation),成立于1979年，总部位于美国,连同其附属公司，从事传染病点保健和生殖与妇女健康的诊断解决方案的开发，制造及销售。公司现拥有员工共322人。是一家在美国纳斯达克上市的综合性临床诊断产品生产商和健康服务研发型企业,股票代码:(Nasdaq: QDEL)，其部分快速诊断产品占据美国主流市场。主要产品包括传染性疾病的诊断、生殖健康及孕期诊断、癌症辅助诊断、骨质疏松症辅助诊断及自身免疫疾病的辅助诊断，旗下品牌主要有：Metra， Quidel ， QuickVue ，QuickVue In-Line ，QuickVue Advance，QuickVue+，RapidVue 等。
主营业务名称 其他产品 生殖和妇女的健康 传染病产品
主营业务内容 其他产品：免疫大便潜血试验，幽门螺旋杆菌测试，临床实验和研究试验

生殖和妇女的健康：包括怀孕，衣原体，细菌性阴道病和骨骼健康

传染病产品：如流感， A组链球菌和呼吸道合胞病毒


Quidel Corporation (Nasdaq: QDEL) is a leader serving to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health.

Our products provide healthcare professionals with accurate and cost-effective diagnostic information at the POC. We sell our products to professionals for use in physician's offices, hospitals, clinical laboratories, and wellness screening centers. Our products are focused substantially on family health in areas such as pregnancy, infectious diseases, general health screening, oncology, bone health and autoimmune disorders.

Quidel commenced operations in 1979 and we launched our first products, dipstick-based pregnancy tests, in 1984. Our product base and technology platforms have expanded through internal development and acquisitions of other products and technologies. The current product areas are pregnancy, infectious diseases, oncology, autoimmune diseases and osteoporosis, for professional and research use. During the early 1990's, Quidel successfully embarked on a mission to build its own branded business and market franchises in the professional use markets. As a result, sales are primarily driven by our branded business under the QuickVue® brand name, and the Company enjoys excellent product recognition in its target markets.

The Company continues to increase its research and development efforts and to accelerate the rate of new product introductions. In January 2006, we launched our QuickVue® iFOB (immunochemical Fecal Occult Blood) test for the qualitative detection of blood in stool. Blood in stool is an indication of a number of gastrointestinal disorders, including colorectal cancer.

The strength of Quidel's international distribution strategy is reflected in the success of QuickVue® Rapid SP Influenza in Japan, the world's second largest flu market. We are extending the QuickVue® brand in select Asian and European markets, and will use the Japanese market as a template for penetrating additional countries with appropriate products. We sell through sales representatives for Europe, Middle East, Africa, Asia-Pacific, Latin America and, other international locations, by channeling products through distributor organizations and sales agents. We market our products in the U.S. through a network of national and regional distributors, supported by a direct sales force, and were pleased to be recognized by three of the largest U.S. medical supply distributors as "Supplier of the Year" within the last year.